IL-18–secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Patients with small cell lung cancer (SCLC) generally have a poor prognosis and a median overall survival of only about 13 months, indicating the urgent need for novel therapies. Delta-like protein 3 (DLL3) has been identified as a tumor-specific cell surface marker on neuroendocrine cancers, including SCLC. In this study, we developed a chimeric antigen receptor (CAR) against DLL3 that displays antitumor efficacy in xenograft and murine SCLC models. CAR T cell expression of the proinflammatory cytokine IL-18 greatly enhanced the potency of DLL3-targeting CAR T cell therapy. In a murine metastatic SCLC model, IL-18 production increased the activation of both CAR T cells and endogenous tumor-infiltrating lymphocytes. We also observed an increased infiltration, repolarization, and activation of antigen-presenting cells. Additionally, human IL-18-secreting anti-DLL3 CAR T cells showed an increased memory phenotype, less exhaustion, and induced durable responses in multiple SCLC models, an effect that could be further enhanced with anti-PD-1 blockade. All together, these results define DLL3-targeting CAR T cells that produce IL-18 as a potentially promising novel strategy against DLL3-expressing solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“The addition of immune checkpoint blockade (ICB) has not led to a similar benefit as that seen in other cancers with high tumor mutation burdens, such as melanoma (3), a difference that might be attributable to the notably low MHC-I expression on SCLC cells (4, 5).”
First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., Huemer, F., Losonczy, G., Johnson, M. L., Nishio, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809064 · Cited by 3,586 · cited 1×
“Despite initial sensitivity to chemotherapy, metastatic SCLC almost always recurs, leading to a median overall survival of approximately 13 months (2).”
Rudin, C. M., Brambilla, E., Faivre-Finn, C., & Sage, J. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00235-0 · Cited by 1,570
Self-citationEngineering strategies to overcome the current roadblocks in CAR T cell therapy
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,472 · cited 12×
“IL-18 stimulated persistence and activation of both CAR T cells and tumor-reactive endogenous T cells, as well as myeloid cells in the TME.”
InfluentialSelf-citationPegram, H. J., Lee, J. C., Hayman, E. G., Imperato, G. H., Tedder, T. F., Sadelain, M., & Brentjens, R. J. (2012) · Blood · doi:10.1182/blood-2011-12-400044 · Cited by 678
Self-citationSaunders, L. R., Bankovich, A. J., Anderson, W. C., Aujay, M. A., Bheddah, S., Black, K., Desai, R., Escarpe, P. A., Hampl, J., Laysang, A., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac9459 · Cited by 600
Self-citationRudin, C. M., Pietanza, M. C., Bauer, T. M., Ready, N., Morgensztern, D., Glisson, B. S., Byers, L. A., Johnson, M. L., Burris, H. A., Robert, F., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30565-4 · Cited by 574
Self-citationChmielewski, M., Kopecky, C., Hombach, A. A., & Abken, H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0103 · Cited by 562
Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18
Hu, B., Ren, J., Luo, Y., Keith, B., Young, R. M., Scholler, J., Zhao, Y., & June, C. H. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.002 · Cited by 506
CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer
Weiskopf, K., Jahchan, N. S., Schnorr, P. J., Cristea, S., Ring, A. M., Maute, R. L., Volkmer, A. K., Volkmer, J.-P., Liu, J., Lim, J. S., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81603 · Cited by 444 · cited 1×
“SCLC tumors contain many macrophages (24), underlining the importance of repolarizing macrophages from an immunosuppressive to a proinflammatory state.”
Self-citationChmielewski, M., & Abken, H. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.063 · Cited by 429 · cited 1×
“IL-18 secretion by the CAR T cells can shift an immunosuppressive microenvironment into a proinflammatory state (20, 22) by increasing the infiltration and activation of CD11b+Gr1– macrophages and MHC-II+ CD11c+ dendritic cells, both at the tumor site and systemically, and reducing CD206+MHC-IIlo M2-like polarization…”
BackgroundIL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo
Koneru, M., Purdon, T. J., Spriggs, D., Koneru, S., & Brentjens, R. J. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.994446 · Cited by 418
Self-citationArmored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
Yeku, O. O., Purdon, T. J., Koneru, M., Spriggs, D., & Brentjens, R. J. (2017) · Scientific Reports · doi:10.1038/s41598-017-10940-8 · Cited by 409
Self-citationDoyle, A., Martin, W. J., Funa, K., Gazdar, A., Carney, D., Martin, S. E., Linnoila, I., Cuttitta, F., Mulshine, J., & Bunn, P. (1985) · The Journal of experimental medicine · doi:10.1084/jem.161.5.1135 · Cited by 382 · cited 1×
“The addition of immune checkpoint blockade (ICB) has not led to a similar benefit as that seen in other cancers with high tumor mutation burdens, such as melanoma (3), a difference that might be attributable to the notably low MHC-I expression on SCLC cells (4, 5).”
Rivière, I., Brose, K., & Mulligan, R. C. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.6733 · Cited by 364 · cited 1×
“Plasmids encoding the human and mouse CAR constructs in a SFG γ-retroviral vector (27) were”
Avanzi, M. P., Yeku, O., Li, X., Wijewarnasuriya, D. P., van Leeuwen, D. G., Cheung, K., Park, H., Purdon, T. J., Daniyan, A. F., Spitzer, M. H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.051 · Cited by 341 · cited 3×
“Together with the increased antitumor TIL response in the ELISpot assay and delayed tumor outgrowth after rechallenge with DLL3KO mSCLC tumors, this suggests that IL-18 stimulates tumor-reactive TILs, which is in line with earlier findings in a CD19+ lymphoma model (20) and may be important for elimination of DLL3– tu…”
Self-citationZhang, L., Kerkar, S. P., Yu, Z., Zheng, Z., Yang, S., Restifo, N. P., Rosenberg, S. A., & Morgan, R. A. (2011) · Molecular Therapy · doi:10.1038/mt.2010.313 · Cited by 293
Chinnasamy, D., Yu, Z., Kerkar, S. P., Zhang, L., Morgan, R. A., Restifo, N. P., & Rosenberg, S. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3050 · Cited by 277
Giffin, M. J., Cooke, K., Lobenhofer, E. K., Estrada, J., Zhan, J., Deegen, P., Thomas, M., Murawsky, C. M., Werner, J., Liu, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2845 · Cited by 258 · cited 1×
“Low-level DLL3 mRNA expression has been detected in pituitary, brain, and testis (9) but, importantly, not on the cell surface of nonmalignant cells (8), making it an attractive tumor-specific target for antibody-drug conjugates (8, 10), bispecific T cell engagers (11, 12), and CAR T cells.”
Kuhn, N. F., Purdon, T. J., van Leeuwen, D. G., Lopez, A. V., Curran, K. J., Daniyan, A. F., & Brentjens, R. J. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.006 · Cited by 243 · cited 1×
“flow cytometry were previously described (30).”
Self-citationIntrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity
Mahadevan, N. R., Knelson, E. H., Wolff, J. O., Vajdi, A., Saigí, M., Campisi, M., Hong, D., Thai, T. C., Piel, B., Han, S., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0913 · Cited by 227 · cited 1×
“The addition of immune checkpoint blockade (ICB) has not led to a similar benefit as that seen in other cancers with high tumor mutation burdens, such as melanoma (3), a difference that might be attributable to the notably low MHC-I expression on SCLC cells (4, 5).”
BackgroundChapman, G., Sparrow, D. B., Kremmer, E., & Dunwoodie, S. L. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddq529 · Cited by 196 · cited 1×
“The inhibitory Notch ligand Delta-like protein 3 (DLL3) (6), a direct transcriptional target of the neuroendocrine transcription factor ASCL1 (7), is expressed specifically on the surface of neuroendocrine cancers, including SCLC (8).”
BackgroundChekmasova, A. A., Rao, T. D., Nikhamin, Y., Park, K. J., Levine, D. A., Spriggs, D. R., & Brentjens, R. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0192 · Cited by 171
Self-citationAscl1 and Neurog2 form novel complexes and regulate Delta-like3 (Dll3) expression in the neural tube
Henke, R. M., Meredith, D. M., Borromeo, M. D., Savage, T. K., & Johnson, J. E. B. (2009) · Developmental Biology · doi:10.1016/j.ydbio.2009.01.007 · Cited by 141 · cited 1×
“The inhibitory Notch ligand Delta-like protein 3 (DLL3) (6), a direct transcriptional target of the neuroendocrine transcription factor ASCL1 (7), is expressed specifically on the surface of neuroendocrine cancers, including SCLC (8).”
BackgroundNoninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer
Sharma, S. K., Pourat, J., Abdel-Atti, D., Carlin, S. D., Piersigilli, A., Bankovich, A. J., Gardner, E. E., Hamdy, O., Isse, K., Bheddah, S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0299 · Cited by 125 · cited 2×
“Low-level DLL3 mRNA expression has been detected in pituitary, brain, and testis (9) but, importantly, not on the cell surface of nonmalignant cells (8), making it an attractive tumor-specific target for antibody-drug conjugates (8, 10), bispecific T cell engagers (11, 12), and CAR T cells.”
Self-citationSmith, E. L., Staehr, M., Masakayan, R., Tatake, I. J., Purdon, T. J., Wang, X., Wang, P., Liu, H., Xu, Y., Garrett-Thomson, S. C., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.03.016 · Cited by 118
Self-citationWermke, M., Felip, E., Gambardella, V., Kuboki, Y., Morgensztern, D., Hamed, Z. O., Liu, M., Studeny, M., & Owonikoko, T. K. (2022) · Future Oncology · doi:10.2217/fon-2022-0196 · Cited by 68
Excessive Costimulation Leads to Dysfunction of Adoptively Transferred T Cells
Wijewarnasuriya, D., Bebernitz, C., Lopez, A. V., Rafiq, S., & Brentjens, R. J. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0908 · Cited by 42
Self-citationTaromi, S., Firat, E., Simonis, A., Braun, L. M., Apostolova, P., Elze, M., Passlick, B., Schumacher, A., Lagies, S., Frey, A., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215697 · Cited by 36
Cited by
Advances and challenges in the treatment of lung cancer
Li, Y., Yan, B., & He, S. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115891 · Cited by 462
CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
Peng, L., Sferruzza, G., Yang, L., Zhou, L., & Chen, S. (2024) · Cellular & Molecular Immunology · doi:10.1038/s41423-024-01207-0 · Cited by 373
Metadata
- Authors
- Jaspers, J. E., Khan, J. F., Godfrey, W. D., Lopez, A. V., Ciampricotti, M., Rudin, C. M., & Brentjens, R. J.
- Venue
- Journal of Clinical Investigation
- Published
- 2023-05-01
- Volume
- 133
- Issue
- 9
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W4360600671
- Cited by
- 190
- References
- 29
- FWCI
- 19.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.